TP53 and colorectal carcinoma: revealed that CRC organoids bearing mutations in the transforming growth factor‐beta, TP53, and Hippo pathways exhibit resistance to Wnt pathway inhibitors,[20] suggesting the need for pathway‐targeted treatment.